Sort
39,280 grants matching “leukemia”
PD-L1 interacts with CD80 and PD-1 to regulate GVHD and GVL activity
$404,275Defu Zeng · Beckman Research Institute/City Of Hope · R01 · FY2018 · CA
A Mouse Model to Assess Long Term Immunotherapy-related Adverse Effects in Children
$404,265Pan Zheng · University Of Maryland Baltimore · R01 · FY2019 · CA
Project 2: The cohesin complex as a tumor suppressor in myeloid leukemia
$404,255Ari M. Melnick · New York University School Of Medicine · P01 · FY2023 · CA
Genomics of AML Prognosis
$404,235Jatinder K. Lamba · University Of Florida · R01 · FY2021 · CA
Biology/prognostic implications of Flt3 mutations in AML
$404,179Fred Hutchinson Cancer Research Center · R01 · FY2005 · CA
Structure/Function of CBFbeta
$404,125Nancy Asmussen Speck · University Of Pennsylvania · R01 · FY2009 · HL
Epigenetic biomarkers of response to Azacytidine in Myelodysplastic Syndromes
$404,125Maria Eugenia Figueroa · University Of Michigan At Ann Arbor · R01 · FY2015 · HL
Development of ChromEx30 for Nanoscale Imaging of Genetic Organization and Disease Phenotypes
$404,117Ons M'saad · Panluminate Inc. · R43 · FY2025 · HG
Computational and Experimental Analysis of Vertebrate RNA Splicing
$404,089Christopher B Burge · Massachusetts Institute Of Technology · R01 · FY2010 · HG
Targeting DOT1L for Degradation in MLL-rearranged Leukemia
$404,076Scott A Armstrong · Dana-Farber Cancer Inst · R01 · FY2020 · CA
Targeting DOT1L for Degradation in MLL-rearranged Leukemia
$404,076Scott A Armstrong · Dana-Farber Cancer Inst · R01 · FY2018 · CA
Targeting DOT1L for Degradation in MLL-rearranged Leukemia
$404,076Scott A Armstrong · Dana-Farber Cancer Inst · R01 · FY2021 · CA
SOUTHWEST ONCOLOGY GROUP
$404,052Wayne State University · U10 · FY2002 · CA
Structure Analysis of Viral Assembly Mechanisms
$404,037Mark Jay Yeager · University Of Virginia · R01 · FY2012 · GM
Leukemia stem cell regulation and resistance
$403,983Ravi Bhatia · University Of Alabama At Birmingham · R01 · FY2024 · CA
Role of the retinoic acid pathway during graft-versus-host disease
$403,959Xiao Chen · Medical College Of Wisconsin · R01 · FY2017 · AI
Improving HSC transplantation by defining novel regulators of engraftment
$403,875Shannon L McKinney-Freeman · St. Jude Children'S Research Hospital · R01 · FY2022 · DK
Improving HSC transplantation by defining novel regulators of engraftment
$403,875Shannon L McKinney-Freeman · St. Jude Children'S Research Hospital · R01 · FY2020 · DK
Defining Nfix's role as a novel key regulator of hematopoietic stem cells
$403,875Shannon L McKinney-Freeman · St. Jude Children'S Research Hospital · R01 · FY2019 · DK
Defining Nfix's role as a novel key regulator of hematopoietic stem cells
$403,875Shannon L McKinney-Freeman · St. Jude Children'S Research Hospital · R01 · FY2017 · DK
Defining Nfix's role as a novel key regulator of hematopoietic stem cells
$403,875Shannon L McKinney-Freeman · St. Jude Children'S Research Hospital · R01 · FY2018 · DK
Defining Nfix's role as a novel key regulator of hematopoietic stem cells
$403,875Shannon L McKinney-Freeman · St. Jude Children'S Research Hospital · R01 · FY2020 · DK
Improving HSC transplantation by defining novel regulators of engraftment
$403,875Shannon L McKinney-Freeman · St. Jude Children'S Research Hospital · R01 · FY2021 · DK
Improving HSC transplantation by defining novel regulators of engraftment
$403,875Shannon L McKinney-Freeman · St. Jude Children'S Research Hospital · R01 · FY2019 · DK
Fusion Proteins in the Molecular Pathogenesis of APL
$403,832Pier Paolo Pandolfi · Sloan-Kettering Inst Can Research · R01 · FY2006 · CA